Alzheimer’s drug study yields positive results, say makers Eisai and Biogen By Reuters

2/2 © Reuters. An Alzheimer’s patient rests on a bench after a walk at the Village Landais Alzheimer site in Dax, France, September 24, 2020. Picture taken on September 24, 2020. REUTERS/Gonzalo Fuentes/File Photo 2/2 By Deena Beasley, Julie Steenhuysen and Rocky Swift (Reuters) – An experimental Alzheimer’s drug made by Eisai Co (OTC:) Ltd … Read more

Biogen Stock Explodes Higher After Alzheimer’s Drug Succeeds In Final-Phase Test

Biogen stock exploded higher Wednesday — bringing shares of other Alzheimer’s plays with it — after its experimental treatment succeeded in a final-phase test. X The results are sorely needed for Biogen (BIIB), which has long struggled to target the neurological disease. In the Phase 3 study, the drug called lecanemab removed built-up plaque in … Read more

Dow Jones Futures Volatile On Bank Of England Reversal; Apple Falls On iPhone Report, Biogen Soars On Alzheimer’s Drug

Dow Jones futures fell in volatile trade Wednesday morning, along with S&P 500 futures and Nasdaq futures, after the Bank of England abruptly announced plans to buy long-term British bonds. The 10-year Treasury yield, which had briefly topped 4%, fell solidly. But a brief boost to stock futures and bond prices began to fade again. … Read more

Dow Jones Futures Fall On Apple iPhone Report, Rising Treasury Yields; Biogen Alzheimer’s Drug Slows Decline

Dow Jones futures fell Wednesday morning, along with S&P 500 futures and Nasdaq futures. The 10-year Treasury yield moved even closer to 4%, while Apple (AAPL) reportedly is reining in iPhone production. X That iPhone report will likely weigh on Apple stock and iPhone chipmakers such as Taiwan Semiconductor (TSM), Broadcom (AVGO), Qualcomm (QCOM) and … Read more

Anticoagulant drug developer Cardrenal Therapeutics files for $10M IPO

designer491 Anticoagulant drug developer Cardrenal Therapeutics (CVKD) has filed for a proposed $10M initial public offering. Cardrenal said in a filing that it considering offering 2M shares at the assumed price of $5 per share, which would raise $10M. Underwriters would be granted a 45-day option to buy up to 300K additional shares. Boustead Securities … Read more

Bulk Drug Pharma Park will ensure pharma units stay in Himachal: CM Thakur

Chief Minister Jai Ram Thakur called on Union Minister for Health and Family Welfare, Chemicals and Fertilizers Mansukh Mandaviya at New Delhi on Wednesday and thanked the Union Minister for allocating Bulk Drug Pharma Park to Himachal Pradesh. He said that Prime Minister Narendra Modi had always accorded priority to the developmental … Read more

Centene to Pay Texas $165 Million in Medicaid Drug Pricing Settlement

Health insurance giant Centene Corp. has agreed to pay $165.6 million to Texas to resolve claims that it overcharged the state’s Medicaid program for pharmacy services. It’s the biggest known payout by the nation’s largest Medicaid insurer over its drug pricing practices. The deal was signed July 11 but hadn’t been publicly announced until Monday … Read more

Only 75% accelerated non-cancer drug approvals led to full approvals – study (NASDAQ:BIIB)

hapabapa/iStock Editorial via Getty Images Highlighting the drawbacks of the FDA’s accelerated approval, a newly published study has found that medications for only 75% of non-oncology conditions where drugs were cleared through the pathway were converted to regular approvals. The accelerated approval program created in 1992 allows the FDA to clear drugs based on surrogate … Read more

Mundra port drug haul: Court remands three accused to 10-day NIA custody

A special court on Saturday remanded an Afghan national and two others to 10-day custody of the National Investigation Agency (NIA) in connection with the September 2021 seizure of heroin worth Rs 21,000 crore from Mundra port in Gujarat’s Kutch district. The trio were arrested by the NIA from Delhi and produced … Read more

Valneva and IDT Biologika to end COVID vaccine drug substance manufacturing deal

-slav- French biotech Valneva (NASDAQ:VALN) on Friday said it had agreed to terminate its COVID-19 vaccine drug substance manufacturing agreement with contract development organization IDT Biologika following the suspension of the manufacturing of the shot. The European Commission in early June sharply reduced its order for doses amidst a delay in the shot’s approval. Valneva … Read more